Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE

Over the past decade, the number of therapeutic options for metastatic colorectal cancer (mCRC) have substantially improved, resulting in an estimated 50%-63% of patients receiving third-line therapy. This necessitates judicious selection of therapy in later-line settings.1,2 Landmark trials confirmed survival benefit with the addition of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to cytotoxic therapy in first-line treatment of mCRC…